Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease

Journal of Huntington's Disease

Volumn 4, Issue 2, 2015, Pages 131-140

  Tedroff, Joakim ^a   Waters, Susanna ^b   Barker, Roger A ^c   Roos, Raymund ^d   Squitieri, Ferdinando ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e IRCCS NEUROMED   (Italy)

Author keywords

antipsychotics; dopamine; Huntington disease; observational study; tetrabenazine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TETRABENAZINE; TIAPRIDE; VALPROIC ACID; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; BRADYKINESIA; CAG REPEAT; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DYSTONIA; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MENTAL DETERIORATION; MOTOR DYSFUNCTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; COMPLICATION; DRUG EFFECTS; FEMALE; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MOTOR ACTIVITY; REGISTER; STATISTICAL MODEL;

ADULT; ANTIPSYCHOTIC AGENTS; DISEASE PROGRESSION; DOPAMINE AGENTS; FEMALE; HUMANS; HUNTINGTON DISEASE; LINEAR MODELS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PRINCIPAL COMPONENT ANALYSIS; REGISTRIES;

EID: 84961722007     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-150143     Document Type: Article

References (28)

1. Walker FO. Huntington's disease. Lancet. 2007;369(9557):218-28.
2. Ross CA, Margolis RL, Rosenblatt A, Ranen NG, Becher MW, Aylward E. Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). Medicine (Baltimore). 1997;76(5):305-38.
3. Bonelli R, Wenning G. Pharmacological management of Huntington's disease: An evidence-based review. Curr Pharm Des. 2006;12(21):2701-3720.
4. Priller J, Ecker D, Landwehrmeyer B, Crauford D. A Europe-wide assessment of current medication choices in Huntington's disease. Mov Disord. 2008;23(12):1788.
5. Jeste DV, Lohr JB, Eastham JH, Rockwell E, Caligiuri MP. Adverse neurobiological effects of long-term use of neuroleptics: Human and animal studies. J Psychiatr Res. 1998;32(3-4):201-14.
6. Thomas EA. Molecular profiling of antipsychotic drug function: Convergent mechanisms in the pathology and treatment of psychiatric disorders. Mol Neurobiol. 2006;34(2):109-28.
7. Fatemi SH, Reutiman TJ, Folsom TD, Bell C, Nos L, Fried P, Pearce DA, Singh S, Siderovski DP, Willard FS, Fukuda M. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology. 2006;31(9):1888-99.
8. Ma D, Chan MK, Lockstone HE, Pietsch SR, Jones DN, Cilia J, Hill MD, Robbins MJ, Benzel IM, Umrania Y, Guest PC, Levin Y, Maycox PR, Bahn S. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J Proteome Res. 2009;8(7):3284-97.
9. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: A comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology. 2005;30(9):1649-61.
10. Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR, Lewis DA. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 2008;63(8):759-65.
11. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: A longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68(2):128-37.
12. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37(8):1680-91.
13. Scherk H, Falkai P. Effects of antipsychotics on brain structure. Curr Opin Psychiatry. 2006;19(2):145-50.
14. Ebdrup BH, Norbak H, Borgwardt S, Glenthoj B. Volumetric changes in the basal ganglia after antipsychotic monotherapy: A systematic review. Curr Med Chem. 2013;20(3):438-47.
15. Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831-9.
16. Shoulson I, Odoroff C, Oakes D, Behr J, Goldblatt D, Caine E, Kennedy J, Miller C, Bamford K, Rubin A, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol. 1989;25(3):252-9.
17. Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, Ramos-Arroyo MA, Snodgrass SR, Bonilla E, Moreno H, et al. Huntington's disease in Venezuela: Neurologic features and functional decline. Neurology. 1986;36(2):244-9.
18. Shoulson I. Huntington disease: Functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology. 1981;31(10):1333-5.
19. Penney JBJ, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Neurology. 1997;41(5):689-92.
20. Jackson JE. A User's Guide to Principal Components. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 1991.
21. Lipton SA. Pathologically-activated therapeutics for neuroprotection: Mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007;8(5):621-32.
22. Zadori D, Geisz A, Vamos E, Vecsei L, Klivenyi P. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav. 2009;94(1):148-53.
23. Waters S, Tedroff J, Waters N, EHDN. Correlations between functional measures, voluntary and involuntary motor symptoms in HD -multivariate analysis of cross-sectional and longitudinal registry data. J Neurol Neurosurg Psychiatry. 2010;81(A25-A26).
24. Van Vugt JP, Piet K, Vink L, Siesling S, Zwinderman A, Middelkoop H, Roos RA. Objective assessment of motor slowness in Huntington's disease: Clinical correlates and 2-year follow-up. Mov Disord. 2004;19(3):285-97.
25. Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB. Observing Huntington's disease: The European Huntington's Disease Network's REGISTRY. J Neurol Neurosurg Psychiatry. 2011;82(12):1409-12.
26. de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J; MermaiHD study investigators. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049-57.
27. Armstrong MJ, Miyasaki JM. Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(6):597-603.
28. Desamericq G, Dolbeau G, Verny C, Charles P, Durr A, Youssov K, Simonin C, Azulay JP, Tranchant C, Goizet C, Damier P, Broussolle E, Demonet JF, Morgado G, Cleret de Langavant L, Macquin-Mavier I, Bachoud-Lévi AC, Maison P. Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort. PLoS One. 2014;9(1):e85430.